NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.19, Iss.2, 2010-02, pp. : 305-310

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

NX 1207 is promising for the treatment of benign prostatic hyperplasia

Inpharma, Vol. 1, Iss. 1617, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Investigational therapies targeted to the treatment of benign prostatic hyperplasia

By Gravas Stavros de la Rosette Jean JMCH

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 3, 2013-03 ,pp. : 357-368

Informa Healthcare

Access to resources Recommend Favorite

Treatment options for benign prostatic hyperplasia

By Thurlow R.J.

Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. : 225-246

Informa Healthcare

Access to resources Recommend Favorite

Dutasteride for the treatment of benign prostatic hyperplasia

By Wu Christopher Kapoor Anil

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1399-1408

Informa Healthcare

Access to resources Recommend Favorite

Benign prostatic hyperplasia: an insight into current investigational medical therapies

By Tiwari Atul Krishna N S Nanda Kamna Chugh Anita

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 11, 2005-11 ,pp. : 1359-1372

Informa Healthcare

Access to resources Recommend Favorite